Schneider K, Furrer M, Weber E, Siebenmann R, Gallino A, Turina M
Klinik für Herzgefässchirurgie, Departement für Chirurgie, Universitätsspital, Zürich.
Schweiz Med Wochenschr. 1988 Jan 9;118(1):3-9.
Today survival rates after heart transplantation of around 80% at 1 year and around 65% at 5 years are realistic. Most patients attain NYHA functional class I. Due to progress in donor and recipient selection, in immunotherapy, and in a systematic follow-up program post transplant, heart transplantation today has become an accepted treatment in special forms of terminal heart disease. Between September 23, 1985, and May 15, 1987, 19 patients were transplanted in Zurich. After an average of 7 months (1-20), 18 patients are alive with NYHA functional class I. The follow-up program checks systematically for the three main problems post transplant (rejection, infection, and drug-induced side-effects). Regular endomyocardial biopsy is the gold standard for diagnosis of rejection. Non-invasive methods, such as cyto-immunological monitoring, neopterin, or beta 2-microglobulin, are not a substitute but valuable adjunctive diagnostic methods.
如今,心脏移植术后1年的存活率约为80%,5年的存活率约为65%,这是切实可行的。大多数患者达到纽约心脏协会(NYHA)心功能I级。由于在供体和受体选择、免疫治疗以及移植后系统随访计划方面取得的进展,如今心脏移植已成为特殊类型终末期心脏病的一种公认治疗方法。1985年9月23日至1987年5月15日期间,苏黎世有19例患者接受了心脏移植。平均7个月(1 - 20个月)后,18例患者存活,心功能为NYHA I级。随访计划系统地检查移植后三个主要问题(排斥反应、感染和药物引起的副作用)。定期心内膜心肌活检是诊断排斥反应的金标准。非侵入性方法,如细胞免疫监测、新蝶呤或β2 -微球蛋白,并非替代方法,而是有价值的辅助诊断方法。